title: TGFβ1 Leu10Pro polymorphism contributes to the development of prostate cancer: evidence from a meta-analysis.
abstract: Transforming growth factor-β1 (TGFβ1) plays a significant role in regulating cellular proliferation and apoptosis. A large number of studies related to the association between TGFβ1 Leu10Pro polymorphism and prostate cancer (PC) risk, but get conflicting results. We performed a meta-analysis based on six studies, assessing the strength of the association using odds ratios (OR) with 95% confidence intervals (CI). Overall, our evidence has indicated that TGFβ1 Leu10Pro polymorphism had significantly increased PC risk in the allele comparison model (OR = 1.081, 95% CI = 1.003-1.165, Pheterogeneity = 0.141, P = 0.041). In the stratified analysis by ethnicity, the same results were found among Caucasians (for heterozygote model, OR = 1.741, 95% CI = 1.004-3.020, Pheterogeneity = 0.000, P = 0.049; recessive model, OR = 1.339, 95% CI = 1.045-1.717, Pheterogeneity = 0.020, P = 0.021; allele comparison model, OR = 1.091, 95% CI = 1.005-1.184, Pheterogeneity = 0.048, P = 0.037). In conclusion, this meta-analysis suggested that TGFβ1 Leu10Pro polymorphism contributed to the development of PC. A well-designed and larger study is still required to evaluate this polymorphism and PC risk.
authors: Department of Urology, the Second Hospital of Tianjin Medical University, Tianjin Institute of Urology, Tianjin, 300211, China.
authors: Qiliang
authors: Q
authors: Cai
authors: Yang
authors: Y
authors: Tang
authors: Minghao
authors: M
authors: Zhang
authors: Zhiqun
authors: Z
authors: Shang
authors: Gang
authors: G
authors: Li
authors: Jing
authors: J
authors: Tian
authors: Ning
authors: N
authors: Jiang
authors: Changyi
authors: C
authors: Quan
authors: Yuanjie
authors: Y
authors: Niu
mesh_terms: D000483:Alleles; D019943:Amino Acid Substitution; D063646:Carcinogenesis / Q000235:genetics; D016022:Case-Control Studies; D003062:Codon; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000208:ethnology / Q000235:genetics*; D017594:Publication Bias; D053773:Transforming Growth Factor beta1 / Q000235:genetics*
chemical_list: D003062:Codon; D053773:Transforming Growth Factor beta1
references: Structure. 2002 Jul;10(7):913-9
references: 12121646
references: Somat Cell Mol Genet. 1986 May;12(3):281-8
references: 3459257
references: World J Urol. 2009 Jun;27(3):371-7
references: 19039592
references: Cancer Sci. 2003 Mar;94(3):230-4
references: 12824914
references: BMC Med Res Methodol. 2002 Aug 09;2:10
references: 12171604
references: Prostate. 1997 Apr 1;31(1):61-70
references: 9108888
references: Cancer Invest. 2007 Dec;25(8):726-32
references: 18058470
references: Carcinogenesis. 2004 Feb;25(2):237-40
references: 14604900
references: Cancer Epidemiol Biomarkers Prev. 2004 May;13(5):759-64
references: 15159307
references: Microsc Res Tech. 2001 Feb 15;52(4):411-9
references: 11170300
references: Hum Mol Genet. 1999 Jan;8(1):93-7
references: 9887336
references: J Natl Cancer Inst. 1959 Apr;22(4):719-48
references: 13655060
references: Control Clin Trials. 1986 Sep;7(3):177-88
references: 3802833
references: Ann Intern Med. 1997 Nov 1;127(9):820-6
references: 9382404
references: Front Biosci. 2006 May 01;11:1388-413
references: 16368524
references: Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6
references: 17646272
references: Circulation. 2000 Jun 20;101(24):2783-7
references: 10859282
references: BMJ. 1997 Sep 13;315(7109):629-34
references: 9310563
references: Eur J Cancer. 2005 Apr;41(6):846-57
references: 15808954
references: N Engl J Med. 2000 May 4;342(18):1350-8
references: 10793168
references: Adv Cancer Res. 1997;71:165-207
references: 9111866